vs

Side-by-side financial comparison of ULTRALIFE CORP (ULBI) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $48.5M, roughly 1.5× ULTRALIFE CORP). ULTRALIFE CORP runs the higher net margin — -15.3% vs -49.0%, a 33.7% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 10.6%). ULTRALIFE CORP produced more free cash flow last quarter ($607.0K vs $-84.7M).

Ultralife Corporation designs and manufactures batteries and communications systems worldwide. Ultralife serves government and defense, medical, safety and security, energy, robotics and other customers across the globe through the design and development of a range of products. Founded in 1991 when launched as an Initial Public Offering (IPO) evolving from Kodak’s Ultra Technologies battery division, and headquartered in Newark, New York, the Company’s business segments include battery and en...

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

ULBI vs VRDN — Head-to-Head

Bigger by revenue
VRDN
VRDN
1.5× larger
VRDN
$70.6M
$48.5M
ULBI
Growing faster (revenue YoY)
VRDN
VRDN
+81947.6% gap
VRDN
81958.1%
10.6%
ULBI
Higher net margin
ULBI
ULBI
33.7% more per $
ULBI
-15.3%
-49.0%
VRDN
More free cash flow
ULBI
ULBI
$85.3M more FCF
ULBI
$607.0K
$-84.7M
VRDN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ULBI
ULBI
VRDN
VRDN
Revenue
$48.5M
$70.6M
Net Profit
$-7.4M
$-34.6M
Gross Margin
24.9%
Operating Margin
-21.9%
-56.7%
Net Margin
-15.3%
-49.0%
Revenue YoY
10.6%
81958.1%
Net Profit YoY
-3925.8%
54.9%
EPS (diluted)
$-35.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ULBI
ULBI
VRDN
VRDN
Q4 25
$48.5M
Q3 25
$43.4M
$70.6M
Q2 25
$48.6M
Q1 25
$50.7M
Q4 24
$43.9M
Q3 24
$35.7M
Q2 24
$43.0M
Q1 24
$41.9M
Net Profit
ULBI
ULBI
VRDN
VRDN
Q4 25
$-7.4M
Q3 25
$-1.2M
$-34.6M
Q2 25
$879.0K
Q1 25
$1.9M
Q4 24
$194.0K
Q3 24
$258.0K
Q2 24
$3.0M
Q1 24
$2.9M
Gross Margin
ULBI
ULBI
VRDN
VRDN
Q4 25
24.9%
Q3 25
22.2%
Q2 25
23.9%
Q1 25
25.1%
Q4 24
24.2%
Q3 24
24.3%
Q2 24
26.9%
Q1 24
27.4%
Operating Margin
ULBI
ULBI
VRDN
VRDN
Q4 25
-21.9%
Q3 25
-2.2%
-56.7%
Q2 25
4.6%
Q1 25
6.7%
Q4 24
3.4%
Q3 24
1.4%
Q2 24
9.1%
Q1 24
9.7%
Net Margin
ULBI
ULBI
VRDN
VRDN
Q4 25
-15.3%
Q3 25
-2.8%
-49.0%
Q2 25
1.8%
Q1 25
3.7%
Q4 24
0.4%
Q3 24
0.7%
Q2 24
6.9%
Q1 24
6.9%
EPS (diluted)
ULBI
ULBI
VRDN
VRDN
Q4 25
$-35.00
Q3 25
$-0.07
Q2 25
$0.05
Q1 25
$0.02
Q4 24
$37.72
Q3 24
$0.02
Q2 24
$0.18
Q1 24
$0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ULBI
ULBI
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$9.3M
$490.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$130.0M
$503.0M
Total Assets
$216.9M
$577.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ULBI
ULBI
VRDN
VRDN
Q4 25
$9.3M
Q3 25
$490.9M
Q2 25
Q1 25
Q4 24
$6.9M
Q3 24
$6.8M
Q2 24
$6.7M
Q1 24
$10.1M
Total Debt
ULBI
ULBI
VRDN
VRDN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$55.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ULBI
ULBI
VRDN
VRDN
Q4 25
$130.0M
Q3 25
$137.3M
$503.0M
Q2 25
$138.4M
Q1 25
$136.4M
Q4 24
$134.0M
Q3 24
$134.5M
Q2 24
$133.2M
Q1 24
$128.8M
Total Assets
ULBI
ULBI
VRDN
VRDN
Q4 25
$216.9M
Q3 25
$222.2M
$577.1M
Q2 25
$221.0M
Q1 25
$223.8M
Q4 24
$220.5M
Q3 24
$172.4M
Q2 24
$169.8M
Q1 24
$180.6M
Debt / Equity
ULBI
ULBI
VRDN
VRDN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.41×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ULBI
ULBI
VRDN
VRDN
Operating Cash FlowLast quarter
$1.5M
$-84.6M
Free Cash FlowOCF − Capex
$607.0K
$-84.7M
FCF MarginFCF / Revenue
1.3%
-120.1%
Capex IntensityCapex / Revenue
1.8%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$7.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ULBI
ULBI
VRDN
VRDN
Q4 25
$1.5M
Q3 25
$198.0K
$-84.6M
Q2 25
$5.9M
Q1 25
$3.4M
Q4 24
$3.0M
Q3 24
$4.7M
Q2 24
$8.9M
Q1 24
$-81.0K
Free Cash Flow
ULBI
ULBI
VRDN
VRDN
Q4 25
$607.0K
Q3 25
$-797.0K
$-84.7M
Q2 25
$4.8M
Q1 25
$2.5M
Q4 24
$2.4M
Q3 24
$4.2M
Q2 24
$8.6M
Q1 24
$-453.0K
FCF Margin
ULBI
ULBI
VRDN
VRDN
Q4 25
1.3%
Q3 25
-1.8%
-120.1%
Q2 25
10.0%
Q1 25
4.9%
Q4 24
5.6%
Q3 24
11.6%
Q2 24
19.9%
Q1 24
-1.1%
Capex Intensity
ULBI
ULBI
VRDN
VRDN
Q4 25
1.8%
Q3 25
2.3%
0.2%
Q2 25
2.3%
Q1 25
1.8%
Q4 24
1.4%
Q3 24
1.7%
Q2 24
0.8%
Q1 24
0.9%
Cash Conversion
ULBI
ULBI
VRDN
VRDN
Q4 25
Q3 25
Q2 25
6.75×
Q1 25
1.81×
Q4 24
15.70×
Q3 24
18.40×
Q2 24
3.01×
Q1 24
-0.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ULBI
ULBI

Commercial$36.3M75%
Government Defense$9.6M20%
Communications Systems Segment$2.6M5%

VRDN
VRDN

Segment breakdown not available.

Related Comparisons